Evidence map›Paper›PMID 39370258›Full record

ArticleInternal medicine (Tokyo, Japan)2025

Successful Treatment of Monoclonal Immunotactoid Glomerulopathy Associated with Chronic Lymphocytic Leukemia Using Ibrutinib.

Ayano Saito, Yoshihiro Kameoka, Kumi Ubukawa, Hiroshi Ohtani, Fumito Abe, Masaya Saito, Mako Hashimoto, Tatsuro Kanazawa, Atsushi Komatsuda, Naoto Takahashi

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ayano SaitoDepartment of Hematology, Nephrology, and Rheumatology, Akita University Graduate School of Medicine, Japan.
Yoshihiro KameokaDepartment of Hematology, Nephrology, and Rheumatology, Akita University Graduate School of Medicine, Japan.
Kumi UbukawaDepartment of Internal Medicine, Yuri-Kumiai General Hospital, Japan.
Hiroshi OhtaniDepartment of Nephrology, Akita Kousei Medical Center, Japan.
Fumito AbeDepartment of Hematology, Nephrology, and Rheumatology, Akita University Graduate School of Medicine, Japan.
Masaya SaitoDepartment of Hematology, Nephrology, and Rheumatology, Akita University Graduate School of Medicine, Japan.
Mako HashimotoDepartment of Hematology, Nephrology, and Rheumatology, Akita University Graduate School of Medicine, Japan.
Tatsuro KanazawaDepartment of Hematology, Nephrology, and Rheumatology, Akita University Graduate School of Medicine, Japan.
Atsushi KomatsudaDepartment of Internal Medicine, Ogachi Central Hospital, Japan.
Naoto TakahashiDepartment of Hematology, Nephrology, and Rheumatology, Akita University Graduate School of Medicine, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 71-year-old woman developed nephrotic syndrome during 10-year follow-up for chronic lymphocytic leukemia. A renal biopsy sample analysis revealed IgG1-lambda-positive monoclonal immunotactoid glomerulopathy (mITG). The patient was treated with ibrutinib, a Bruton tyrosine kinase inhibitor, and complete renal remission was achieved after 24 months. ITG is a rare disease that is characterized by glomerular deposition. In particular, mITG, which presents immune deposits that exhibit light-chain restriction, is often associated with hematologic disorders. Most patients with mITG receive immunosuppressive therapy and/or chemotherapy; however, to our knowledge, there have been no reports of treatment with ibrutinib.

Indexed as

Leukemia, Lymphocytic, Chronic, B-CellNephrotic SyndromePyrazolesPyrimidinesAdenineAgedFemaleHumansPiperidinesProtein Kinase InhibitorsTreatment OutcomeAdenineibrutinibPiperidinesProtein Kinase InhibitorsPyrazolesPyrimidinesBruton's tyrosine kinase inhibitorchronic lymphocytic leukemiaibrutinibIgG1-lambda monoclonal gammopathyimmunotactoid glomerulopathynephrotic syndrome

Identifiers

PMID39370258
PMCPMC12120228

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.